Top

Molecular Cancer

Published in:

Open Access 01-12-2017 | Research

Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma

Published in: Molecular Cancer | Issue 1/2017

Title: Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma
Publication date: 01-12-2017
Published in: Molecular Cancer / Issue 1/2017
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-017-0666-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1/2017

ITIH5 mediates epigenetic reprogramming of breast cancer cells

Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis

SUMO1 modification of KHSRP regulates tumorigenesis by preventing the TL-G-Rich miRNA biogenesis

Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma

STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4

PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer